As predicted by the in vitro studies, we found that trastuzumab treatment moderately slowed tumor growth with shCtrl cells, while significantly reduced tumor growth in SHCBP1-depleted cell xenograft models (Fig. 3i and Supplementary Fig. 3c, d). This evidence concerns the gene SHCBP1 and neoplasm.